Clinical features of anthracycline-induced cardiotoxicity in patients with malignant lymphoma who received a CHOP regimen with or without rituximab: A single-center, retrospective observational study.

CHOP regimen anthracycline‐induced cardiotoxicity malignant lymphoma recovery from cardiotoxicity re‐cardiotoxicity

Journal

EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 04 07 2020
revised: 16 09 2020
accepted: 20 09 2020
entrez: 18 7 2022
pubmed: 3 10 2020
medline: 3 10 2020
Statut: epublish

Résumé

We investigated the incidence of cardiotoxicity, its risk factors, and the clinical course of cardiac function in patients with malignant lymphoma (ML) who received a cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen. Among all ML patients who received a CHOP regimen with or without rituximab from January 2008 to December 2017 in Nagoya City University hospital, 229 patients who underwent both baseline and follow-up echocardiography and had baseline left ventricular ejection fraction (LVEF) ≥50% were analyzed, retrospectively. Cardiotoxicity was defined as a ≥10% decline in LVEF and LVEF < 50%; recovery from cardiotoxicity was defined as a ≥5% increase in LVEF and LVEF ≥50%. Re-cardiotoxicity was defined as meeting the criteria of cardiotoxicity again. With a median follow-up of 1132 days, cardiotoxicity, symptomatic heart failure, and cardiovascular death were observed in 48 (21%), 30 (13%), and 5 (2%) patients, respectively. Multivariate analysis demonstrated that history of ischemic heart disease (hazard ratio (HR), 3.15; 95% CI, 1.17-8.47,

Identifiants

pubmed: 35845008
doi: 10.1002/jha2.110
pii: JHA2110
pmc: PMC9176145
doi:

Types de publication

Journal Article

Langues

eng

Pagination

498-506

Informations de copyright

© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Arch Med Sci. 2014 Oct 27;10(5):1007-18
pubmed: 25395954
Circulation. 2015 Jun 2;131(22):1981-8
pubmed: 25948538
J Clin Oncol. 1984 Feb;2(2):112-7
pubmed: 6699662
Clin Drug Investig. 2009;29(2):131-7
pubmed: 19133708
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
pubmed: 24703918
J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
pubmed: 20117401
J Am Coll Cardiol. 2012 Dec 11;60(23):2384-90
pubmed: 23141499
J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62
pubmed: 17161256
Circulation. 2019 Mar 26;139(13):e579-e602
pubmed: 30786722
Chemotherapy. 2018;63(4):238-245
pubmed: 30372698
Circulation. 2014 Jun 10;129(23):2440-92
pubmed: 24589852
Indian J Pharmacol. 2016 Sep-Oct;48(5):490-497
pubmed: 27721532
Heart. 2018 Jun;104(12):971-977
pubmed: 29217634
Cancer. 2003 Jun 1;97(11):2869-79
pubmed: 12767102
Cardiol J. 2014;21(5):509-15
pubmed: 24142687
Lancet Oncol. 2017 Aug;18(8):e445-e456
pubmed: 28759384
FASEB J. 1997 Oct;11(12):931-6
pubmed: 9337145
Asia Pac J Clin Oncol. 2013 Jun;9(2):155-61
pubmed: 22897825
J Am Coll Cardiol. 2013 Jun 11;61(23):2355-62
pubmed: 23583763
N Engl J Med. 1991 Mar 21;324(12):843-5
pubmed: 1997858
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
J Clin Oncol. 2017 Dec 1;35(34):3837-3843
pubmed: 28922087
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
Circulation. 2003 Jul 8;108(1):79-85
pubmed: 12796124
Echocardiography. 2017 Nov;34(11):1593-1600
pubmed: 28942608
BMC Pharmacol Toxicol. 2019 Apr 25;20(1):18
pubmed: 31023386
Cancer Treat Rev. 1993 Jul;19(3):197-228
pubmed: 8334677
Circulation. 2002 Dec 3;106(23):2973-9
pubmed: 12460881
Korean J Intern Med. 2016 Jul;31(4):625-33
pubmed: 27378126
J Pharmacol Exp Ther. 2015 Dec;355(3):516-27
pubmed: 26511374
Curr Cardiol Rep. 2015 Jul;17(7):603
pubmed: 26026994
Curr Pharm Des. 2011;17(20):2113-29
pubmed: 21718248
N Engl J Med. 1993 Apr 8;328(14):1002-6
pubmed: 7680764
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
Circulation. 2000 Oct 24;102(17):2105-10
pubmed: 11044428
Am J Cardiol. 2015 Aug 1;116(3):442-6
pubmed: 26071994
Eur J Heart Fail. 2015 Jan;17(1):81-9
pubmed: 25410653
J Clin Oncol. 2004 May 15;22(10):1864-71
pubmed: 15143078
N Engl J Med. 2000 Apr 13;342(15):1077-84
pubmed: 10760308

Auteurs

Takafumi Nakayama (T)

Department of Cardiology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Yoshiko Oshima (Y)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Shigeru Kusumoto (S)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Junki Yamamoto (J)

Department of Cardiology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Satoshi Osaga (S)

Clinical Research Management Center Nagoya City University Hospital Nagoya Japan.

Haruna Fujinami (H)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Takaki Kikuchi (T)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Tomotaka Suzuki (T)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Haruhito Totani (H)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Shiori Kinoshita (S)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Tomoko Narita (T)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Asahi Ito (A)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Masaki Ri (M)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Hirokazu Komatsu (H)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Kazuaki Wakami (K)

Department of Cardiology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Toshihiko Goto (T)

Department of Cardiology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Tomonori Sugiura (T)

Department of Cardiology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Yoshihiro Seo (Y)

Department of Cardiology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Nobuyuki Ohte (N)

Department of Cardiology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Shinsuke Iida (S)

Department of Hematology and Oncology Nagoya City University Graduate School of Medical Sciences Nagoya Japan.

Classifications MeSH